Pharmacotherapy following myocardial infarction

Czech version

Authors: L. Špinarová ¹; J. Špinar ²; J. Vítovec ¹
Authors‘ workplace: I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ¹; Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ²
Published in: Vnitř Lék 2011; 57(11): 966-969
Category: Birthday

Overview

Early reperfusion is the treatment of choice for acute coronary syndrome. In the Czech Republic, reperfusion therapy is well accessible thanks to the network of 22 catheterization centres. Every year, 28,000 patients are treated using this technique. Successful reperfusion should be followed by life style changes – smoking cessation, maintenance of appropriate body weight etc. These steps than has to be accompanied by effective pharmacotherapy to prevent remodelling of the left ventricle, re-stenosis of the coronary artery, re-thrombosis and arrhythmias. Four drug groups provide the desired effects – renin-angiotensin-aldosterone system blockers, beta--blockers, antiplatelet agents and statins.

Key words:
myocardial infarction – pharmacotherapy

Sources

1. Šimon J et al. Epidemiologie a prevence ischemické choroby srdeční. Praha: Grada Publishing 2001.

2. Špinar J, Vítovec J et al. Ischemická choroba srdeční. Praha: Grada Publishing 2003.

3. Groch L. Co způsobuje pokles úmrtnosti na ischemickou chorobu srdeční? – editorial. Vnitř Lék 2011; 57: 437–438.

4. Shafazand S, Rosengren A, Lampas G et al. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993–2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail 2011; 13: 135–141.

5. ONTARGET study investigators. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

6. Pfeffer MA, McMurray JJ, Velazquez EJ et al. VALIANT Investigators. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349: 1893–1906.

7. Vítovec J, Špinar J. Je kombinace inhibitorů ACE a blokátorů receptorů pro angiotenzin II v léčbě kardiovaskulárních onemocnění indikovaná? Remedia 2009; 19: 149–152.

8. Pepine CJ. INVEST group. Outcomes from randomised trial of calcium antagonist and non calcium antagonist blood pressure treatment strategy in patients with coronary artery disease. JAMA 2003; 290: 2859–2816.

9. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidémií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.

10. Walentin L, Becker RC, Budaj A et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndroms. N Engl J Med 2009; 361: 1045–1057.

11. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

12. Borer JS. Heart rate: from risk marker to risk factor. Eur Heart J Suppl 2008; 10: F2–F6.

13. Bangalore S, Messerli FH, Ou F et al. CRUSADE Investigators. The association of admission heart rate and in-hospital cardiovascular events in patients with non--ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 2010; 31: 552–560.

14. Pilote L, Abrahamowitz M, Rodrigues E et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme converting inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141: 102–112.

15. Hansen ML, Gislason GH, Køber L et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharm 2008; 65: 217–223.

16. Yusuf S, Sleight P, Pogue J et al. The HOPE investigators. Effects of angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.

17. Fox KM. The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.

18. Braunwald E, Domanski MJ, Fowler SE et al. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068.

19. Pedersen TR, Faergeman O, Kastelein JJ et al. Incremental Decrease in End Points Through Aggressive Lipid-Lowering Study Group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2006; 294: 2437–2445.

20. Špinar J, Ludka O, Šenkyříková M et al. Hladiny cholesterolu v závislosti na věku. Vnitř Lék 2009; 55: 724–729.

21. Waters DD, Guyton JR, Herrington DM et al. TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93: 154–158.

22. Pitt B, Remme W, Zannad F et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.

23. Kotseva K, Wood D, De Backer G et al. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929–940.

24. Mayer jr. O, Šimon J, Galovcová M et al. Úroveň sekundární prevence ischemické choroby srdeční u českách pacienců ve studii EUROASPIRE III. Cor Vasa 2008; 50: 156–162.

25. Špinar J, Vítovec J, Špinarová L. FARIM. Farmakoterapie po infarktu myokardu. Vnitř Lék 2011; 57: 778–784.

26. Špinar J, Ludka O, Sepši M et al v zastoupení řešitelů registru: Registr BRNO 2: farmakoterapie po infarktu myokardu. Vnitř Lék 2010; 56: 533–540.